Details of the Drug

General Information of Drug (ID: DM9SX6Y)

Drug Name
INDISULAM
Synonyms
Indisulam; 165668-41-7; E7070; N-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide; UNII-WJ98J3NM90; E-7070; E 7070; N-(3-Chloro-1H-indol-7-yl)-1,4-benzenedisulfonamide; CHEMBL77517; WJ98J3NM90; N1-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide; 1,4-Benzenedisulfonamide, N-(3-chloro-1H-indol-7-yl)-; ER-35744; N-(3-Chloro-1H-indol-7-yl)benzene-1,4disulfonamide; Indisulam (IND); indisulam (e7070); Indisulam (USAN/INN); AC1Q6VCX; AC1L50QL; SCHEMBL91389; N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide; Indisulam [USAN:INN:BAN]
Indication
Disease Entry ICD 11 Status REF
Lymphoma 2A80-2A86 Phase 2 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 385.8
Logarithm of the Partition Coefficient (xlogp) 1.8
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 6
Chemical Identifiers
Formula
C14H12ClN3O4S2
IUPAC Name
4-N-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide
Canonical SMILES
C1=CC2=C(C(=C1)NS(=O)(=O)C3=CC=C(C=C3)S(=O)(=O)N)NC=C2Cl
InChI
InChI=1S/C14H12ClN3O4S2/c15-12-8-17-14-11(12)2-1-3-13(14)18-24(21,22)10-6-4-9(5-7-10)23(16,19)20/h1-8,17-18H,(H2,16,19,20)
InChIKey
SETFNECMODOHTO-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
216468
ChEBI ID
CHEMBL77517
CAS Number
165668-41-7
UNII
WJ98J3NM90
DrugBank ID
DB06370
TTD ID
D04IIU
INTEDE ID
DR0873
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Carbonic anhydrase IX (CA-IX) TT2LVK8 CAH9_HUMAN Modulator [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [3]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Post-Translational Modifications [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Lymphoma
ICD Disease Classification 2A80-2A86
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Carbonic anhydrase IX (CA-IX) DTT CA9 6.08E-15 2.8 7.25
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 1.02E-01 -2.84E-01 -7.34E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 1.62E-02 -4.23E-01 -1.25E+00
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7046).
2 Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-assoc... Bioorg Med Chem Lett. 2004 Jan 5;14(1):217-23.
3 PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression. Clin Pharmacol Ther. 2008 Jun;83(6):829-39.
4 CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity. Clin Cancer Res. 2007 May 15;13(10):2970-6.
5 A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor. Clin Cancer Res. 2004 Jul 15;10(14):4680-7. doi: 10.1158/1078-0432.CCR-04-0229.